{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,20]],"date-time":"2026-10-20T06:01:49Z","timestamp":1792476109116,"version":"4.5.0"},"reference-count":38,"publisher":"Wiley","issue":"6","license":[{"start":{"date-parts":[[2008,5,8]],"date-time":"2008-05-08T00:00:00Z","timestamp":1210204800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Euro J of Neurology"],"published-print":{"date-parts":[[2008,6]]},"abstract":"<jats:p><jats:bold>Background:\u2002<\/jats:bold> Gelsolin is a highly conserved intracellular actin\u2010binding protein with an extracellular isoform, plasma gelsolin, for which there is not yet a clearly defined function.<\/jats:p><jats:p><jats:bold> Materials and methods:\u2002<\/jats:bold> In this study, we determined gelsolin concentrations in blood and cerebrospinal fluid (CSF) obtained from 25 subjects using immunoblotting and a functional assay that quantifies gelsolin\u2019s ability to accelerate actin polymerization.<\/jats:p><jats:p><jats:bold> Results:\u2002<\/jats:bold> The gelsolin concentration in CSF, determined by quantitative immunoblotting was 1.2\u201315.9\u2003\u03bcg\/ml (average 5.9\u2003\u00b1\u20033.8\u2003\u03bcg\/ml). In samples obtained from patients diagnosed with conditions that do not alter standard CSF clinical tests [(idiopathic cephalgia, ischialgia due to discopathy, and idiopathic (Bell\u2019s) facial nerve palsy or entrapment radial neuropathy)], the average gelsolin concentration was 7.2\u2003\u00b1\u20034.3\u2003\u03bcg\/ml. In contrast, the gelsolin concentration in samples obtained from patients diagnosed with multiple sclerosis was 2.1\u2003\u00b1\u20030.7\u2003\u03bcg\/ml, and a similar low concentration was found in a patient recovering from a subarachnoid hemorrhage. The range of CSF gelsolin concentrations determined by the actin polymerization assay was 0.61\u20139.97\u2003\u03bcg\/ml (average 3.6\u2003\u00b1\u20032.2\u2003\u03bcg\/ml). These lower values compared with those obtained from immunoblotting analysis suggest that CSF gelsolin may bind other CSF molecules leading to a reduction of its actin\u2010binding activity.<\/jats:p><jats:p><jats:bold> Conclusions:\u2002<\/jats:bold> The results presented here show that CSF gelsolin concentration is significantly altered in certain neurological conditions, including multiple sclerosis, indicating the possible utility of CSF gelsolin levels for diagnostic purposes.<\/jats:p>","DOI":"10.1111\/j.1468-1331.2008.02133.x","type":"journal-article","created":{"date-parts":[[2008,5,8]],"date-time":"2008-05-08T16:16:07Z","timestamp":1210263367000},"page":"584-588","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":41,"title":["Gelsolin concentration in cerebrospinal fluid from patients with multiple sclerosis and other neurological disorders"],"prefix":"10.1111","volume":"15","author":[{"given":"A.","family":"Kulakowska","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"W.","family":"Drozdowski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Sadzynski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R.","family":"Bucki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P. A.","family":"Janmey","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2008,5,8]]},"reference":[{"key":"e_1_2_4_2_2","doi-asserted-by":"publisher","DOI":"10.1155\/2006\/158797"},{"key":"e_1_2_4_3_2","first-page":"299","article-title":"Identification of the circulating amyloid precursor and other gelsolin metabolites in patients with G654A mutation in the gelsolin gene (Finnish familial amyloidosis): pathogenetic and diagnostic implications","volume":"77","author":"Maury CP","year":"1997","journal-title":"Laboratory Investigation"},{"key":"e_1_2_4_4_2","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.273.26.16319"},{"key":"e_1_2_4_5_2","doi-asserted-by":"publisher","DOI":"10.1002\/pmic.200500294"},{"key":"e_1_2_4_6_2","doi-asserted-by":"publisher","DOI":"10.1021\/pr070220c"},{"key":"e_1_2_4_7_2","doi-asserted-by":"publisher","DOI":"10.1021\/pr025589a"},{"key":"e_1_2_4_8_2","doi-asserted-by":"publisher","DOI":"10.1021\/pr0504788"},{"key":"e_1_2_4_9_2","doi-asserted-by":"publisher","DOI":"10.1038\/281583a0"},{"key":"e_1_2_4_10_2","first-page":"4825","article-title":"Gelsolin\u2010polyphosphoinositide interaction. Full expression of gelsolin\u2010inhibiting function by polyphosphoinositides in vesicular form and inactivation by dilution, aggregation, or masking of the inositol head group","volume":"264","author":"Janmey PA","year":"1989","journal-title":"Journal of Biological Chemistry"},{"key":"e_1_2_4_11_2","doi-asserted-by":"publisher","DOI":"10.1016\/0014-5793(84)81280-6"},{"key":"e_1_2_4_12_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0955-0674(99)80012-X"},{"key":"e_1_2_4_13_2","first-page":"261","article-title":"Circulating actin\u2010gelsolin complexes following oleic acid\u2010induced lung injury","volume":"130","author":"Smith DB","year":"1988","journal-title":"American Journal of Pathology"},{"key":"e_1_2_4_14_2","doi-asserted-by":"crossref","first-page":"8239","DOI":"10.1016\/S0021-9258(18)68469-8","article-title":"Muscle is the major source of plasma gelsolin","volume":"263","author":"Kwiatkowski DJ","year":"1988","journal-title":"Journal of Biological Chemistry"},{"key":"e_1_2_4_15_2","doi-asserted-by":"publisher","DOI":"10.1016\/0304-4165(85)90016-9"},{"key":"e_1_2_4_16_2","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.87.4.1381"},{"key":"e_1_2_4_17_2","doi-asserted-by":"crossref","first-page":"5273","DOI":"10.1016\/S0021-9258(19)67783-5","article-title":"Actin is a noncompetitive plasmin inhibitor","volume":"266","author":"Lind SE","year":"1991","journal-title":"Journal of Biological Chemistry"},{"key":"e_1_2_4_18_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199205143262006"},{"key":"e_1_2_4_19_2","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.275.19.14573"},{"key":"e_1_2_4_20_2","doi-asserted-by":"publisher","DOI":"10.1152\/ajpcell.00510.2006"},{"key":"e_1_2_4_21_2","doi-asserted-by":"publisher","DOI":"10.1021\/bi0503504"},{"key":"e_1_2_4_22_2","doi-asserted-by":"publisher","DOI":"10.1097\/01.CCM.0000253815.26311.24"},{"key":"e_1_2_4_23_2","doi-asserted-by":"publisher","DOI":"10.1164\/ajrccm.160.5.9807137"},{"key":"e_1_2_4_24_2","doi-asserted-by":"publisher","DOI":"10.1164\/ajrccm\/138.2.429"},{"key":"e_1_2_4_25_2","doi-asserted-by":"publisher","DOI":"10.1007\/s004080000084"},{"key":"e_1_2_4_26_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V72.1.214.214"},{"key":"e_1_2_4_27_2","doi-asserted-by":"publisher","DOI":"10.1016\/0016-5085(92)91731-I"},{"key":"e_1_2_4_28_2","doi-asserted-by":"publisher","DOI":"10.1097\/00003246-199704000-00007"},{"key":"e_1_2_4_29_2","doi-asserted-by":"publisher","DOI":"10.1152\/ajpcell.00007.2007"},{"key":"e_1_2_4_30_2","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.33.11.1444"},{"key":"e_1_2_4_31_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0021-9258(18)62016-2"},{"key":"e_1_2_4_32_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1432-1033.1981.tb06167.x"},{"key":"e_1_2_4_33_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2002-06-1672"},{"key":"e_1_2_4_34_2","doi-asserted-by":"publisher","DOI":"10.1007\/s00726-003-0356-6"},{"key":"e_1_2_4_35_2","doi-asserted-by":"publisher","DOI":"10.1002\/pmic.200300715"},{"key":"e_1_2_4_36_2","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1186\/1471-2377-5-22","article-title":"A chronic fatigue syndrome \u2013 elated proteome in human cerebrospinal fluid","volume":"5","author":"Baraniuk JN","year":"2005","journal-title":"BioMed Central Neurology"},{"key":"e_1_2_4_37_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa052643"},{"key":"e_1_2_4_38_2","volume-title":"Methods of using gelsolin to treat or prevent bacterial sepsis","author":"Janmey PA","year":"2006"},{"key":"e_1_2_4_39_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0022-510X(98)00056-2"}],"container-title":["European Journal of Neurology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fj.1468-1331.2008.02133.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/j.1468-1331.2008.02133.x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,10]],"date-time":"2023-10-10T00:04:01Z","timestamp":1696896241000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/j.1468-1331.2008.02133.x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2008,5,8]]},"references-count":38,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2008,6]]}},"alternative-id":["10.1111\/j.1468-1331.2008.02133.x"],"URL":"https:\/\/doi.org\/10.1111\/j.1468-1331.2008.02133.x","archive":["Portico"],"relation":{},"ISSN":["1351-5101","1468-1331"],"issn-type":[{"value":"1351-5101","type":"print"},{"value":"1468-1331","type":"electronic"}],"subject":[],"published":{"date-parts":[[2008,5,8]]},"assertion":[{"value":"2008-05-08","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}